脾胃培源方治疗慢性萎缩性胃炎脾胃虚弱证患者疗效及对胃黏膜三叶因子2、核因子-κB表达的影响  

Efficacy of Piwei Peiyuan Decoction on Patients with Chronic Atrophic Gastritis of Spleen-stomach Weakness Syndrome and Expressions of TFF2 and NF-κB in Gastric Mucosa

作　　者：裴蓓 刘云 宋标 梅语 郑艳敏 李学军[2] PEI Bei;LIU Yun;SONG Biao;MEI Yu;ZHENG Yanmin;LI Xuejun(Anhui University of Chinese Medicine,Hefei 230000,China;The Second Affiliated Hospital of Anhui University of Chinese Medicine,Hefei 230000,China;Hefei Institutes of Physical Science,Chinese Academy of Sciences,Hefei 230000,China)

机构地区：[1]安徽中医药大学,安徽合肥230000 [2]安徽中医药大学第二附属医院,安徽合肥230000 [3]中国科学院合肥物质科学研究院,安徽合肥230000

出　　处：《中国中医药信息杂志》2023年第3期121-125,共5页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：安徽省自然科学基金(2008085MH265)。

摘　　要：目的观察脾胃培源方对慢性萎缩性胃炎脾胃虚弱证患者的临床疗效,以及对胃黏膜三叶因子2(TFF2)、核因子-κB(NF-κB)表达的影响。方法采用随机数字表法将132例患者分为治疗组65例和对照组67例。治疗组予脾胃培源方颗粒,每日1剂,每日2次,口服;对照组予叶酸片,每次1片,每日3次,口服。2组均连续治疗24周。观察2组治疗前后中医症状评分,胃镜及病理评分,血清胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、胃泌素-17(G-17)水平及胃黏膜TFF2、NF-κB水平。监测2组安全性指标。结果治疗过程中治疗组脱落3例、对照组脱落5例。治疗组总有效率为88.71%(55/62),对照组为72.58%(45/62),治疗组疗效优于对照组(P<0.05)。与本组治疗前比较,2组治疗后各项中医症状评分下降(P<0.05);2组治疗后比较,治疗组中医症状评分(除大便不爽评分外)均低于对照组(P<0.05)。与本组治疗前比较,2组治疗后各项胃镜评分、病理评分均下降(P<0.05);2组治疗后比较,治疗组胃镜黏膜色泽评分、黏膜质地评分及各项病理评分均低于对照组(P<0.05)。与本组治疗前比较,2组治疗后血清PGⅠ、PGⅡ、G-17水平上升,胃黏膜TFF2、NF-κB表达水平下降(P<0.05);2组治疗后比较,治疗组上述实验室指标改善优于对照组(P<0.05)。2组治疗过程中均未见明显不良反应。结论脾胃培源方治疗慢性萎缩性胃炎脾胃虚弱证患者效果显著,可有效改善临床症状及胃黏膜病理程度,促进胃黏膜修复,提高患者生活质量。Objective To explore the efficacy of Piwei Peiyuan Decoction on patients with chronic atrophic gastritis of spleen-stomach weakness syndrome and expressions of trefoil factor 2(TFF2)and nuclear factor-κB(NF-κB)in gastric mucosa.Methods Totally 132 chronic atrophic gastritis patients were randomly divided into treatment group(65 cases)and control group(67 cases).The treatment group was given Piwei Peiyuan Decoction granules,one dosage a day,twice a day,orally;the control group was given folic acid tablets,one tablet each time,three times a day,orally.The treatment for both groups lasted for 24 weeks.The TCM symptom scores,gastroscopy and pathological scores,serum PGⅠ,PGⅡ,G-17 levels,gastric mucosal TFF2 and NF-κB level were observed before and after the treatment.Safety indicators of both groups were monitored.Results During the treatment,3 cases were lost in the treatment group and 5 cases were lost in the control group.The total effective rate was 88.71%(55/62)in the treatment group and 72.58%(45/62)in the control group.The therapeutic effect of the treatment group was better than that of the control group(P<0.05).Compared with before treatment,TCM symptom scores in the two groups decreased after treatment(P<0.05);after treatment,the TCM symptom scores in the treatment group(except the score of uncomfortable stool)were lower than those in the control group(P<0.05).Compared with before treatment,the gastroscopic scores and pathological scores of the two groups decreased after treatment(P<0.05);after treatment,the mucosal color score,mucosal texture score and pathological scores in the treatment group were lower than those in the control group(P<0.05).Compared with before treatment,the levels of serum PGⅠ,PGⅡand G-17 in the two groups increased significantly after treatment,and the expression levels of gastric mucosa TFF2 and NF-κB decreased(P<0.05);after treatment,the improvement of the above laboratory indexes in the treatment group was better than that in the control group(P<0.05).There was no obvio

关 键 词：慢性萎缩性胃炎 脾胃培源方 临床治疗 作用机制 

分 类 号：R259.733.2[医药卫生—中西医结合]